Compare Futu Holdings Ltd (FUTU) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Futu Holdings Ltd vs Vertex Pharmaceuticals Incorporated — how do they compare? Futu Holdings Ltd trades at $97.51 (market cap $13.94B), while Vertex Pharmaceuticals Incorporated trades at $477.12 (market cap $121.09B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 8.7× Futu Holdings Ltd's market cap, and Futu Holdings Ltd pays a 2.62% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| FUTU | VRTX | |
|---|---|---|
Market Cap | $13.94B | $121.09B |
Sector | Financials | Health |
52-Week High | $199.04 | $529.59 |
52-Week Low | $89.76 | $366.54 |
Enterprise Value | $13.79B | $115.83B |
Dividend Yield | 2.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FUTU trades at $98.2, up 0.07% on the day, with a bullish technical signal but mixed earnings history including a Q1 2026 miss. The company shows strong fundamentals with 2025 revenue of $22.85B, net income margin of 49.62%, and robust cash flow. However, multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The outlook is clouded by legal risks despite solid profitability and analyst support (58% buy ratings). Investment opportunity hinges on resolution of regulatory allegations, while key risks include potential financial penalties and reputational damage from ongoing litigation.
Vertex Pharmaceuticals (VRTX) trades at $481.35, up 1.06% today, and is near its 52-week high. The stock shows a bullish technical signal with support at $471 and resistance at $482. Fundamentally, the company reported strong 2025 results with $12.0B revenue and $4.0B net income, though 2024 saw a loss. The recent $10B acquisition of Crinetics Pharmaceuticals aims to expand its endocrinology pipeline, potentially adding $5B in peak sales.
Outlook remains positive with analyst consensus at 'Buy' and a $538 price target, implying 12% upside. Key risks include integration challenges from the Crinetics deal and reliance on cystic fibrosis treatments. Earnings growth and pipeline expansion are primary catalysts, but investors should monitor execution on acquisitions and competitive pressures in biotech.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Futu Holdings Ltd
Futu Holdings Ltd is an online broker providing one-stop online investing services. The company provides its services through its digital platform Futu NiuNiu, which includes market data, trading service, and news feed of Hong Kong, Mainland China, Singapore, and United States equity markets. It generates its revenue in the form of brokerage commission and handling charge services.
Read more on FUTU →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
